Notably, compared with no treatment, IL-18BP treatment alleviated MAS, as evidenced by improved cytopenia (Fig. 6F), reduced hemophagocytosis (Fig. 6G), and decreased serum levels of ferritin, IL-1β, and IL-18 on day 8 (Fig. 6H). Here, IL1B is linked to macrophage activation syndrome.